Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
This is a multicenter trial through the Pediatric Blood and Marrow Transplant Consortium.
The Primary hypothesis of this study is that because of its effect as a potent
immunosuppressive agent targeting lymphocytes, pentostatin will show a sustained response in
pediatric subjects with severe chronic GVHD. Secondary hypotheses include that the infection
and toxicity rate of pentostatin in this setting will be acceptable given its lack of severe
myelosuppression, and subjects with refractory chronic GVHD will have significant QOL
impairment and symptomatology. These may change as subjects are being treated for their
chronic GVHD with pentostatin.
Phase:
Phase 2
Details
Lead Sponsor:
Ann & Robert H Lurie Children's Hospital of Chicago